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Abstract 
Neurological manifestations in patients with COVID–19 are
more frequently being reported. Cerebrovascular events have been
reported in around 3% of patients. In this review we summarize the
published literature on cerebrovascular events in patients with
COVID-19 as available on the PubMed database. So far, 3 studies
have reported cerebrovascular events. Cerebrovascular events were
identified on screening patients with decreased consciousness or in
the presence of focal neurological deficits. These events were com-
mon in elderly, critically ill patients and in patients with prior car-
dio-cerebrovascular comorbidities. The diagnosis of cerebrovascu-
lar events was confirmed with computed tomography of the brain in
most studies reporting neurological events. Multiple pathological
mechanisms have been postulated regarding the process of neuro-
logical and vascular injury among which cytokine storm is shown to
correlate with mortality. Patients with severe illness are found to
have a higher cardio- cerebrovascular comorbidity. With an increas-
ing number of cases and future prospective studies, the exact mech-
anism by which these cerebrovascular events occur and attribute to
the poor outcome will be better understood.
Introduction 
After starting in December 2019 at Wuhan, China, the novel
coronavirus 19 (COVID-19) infection has become a pandemic of
global concern. As of 20th April, more than 2.4 million cases have
been reported in 185 countries [1]. A continually rising number of
patients with COVID-19 continues to be a challenge to the med-
ical community and is a major public health concern for experts of
all medical fields. This severe acute respiratory syndrome coron-
avirus -2 is an RNA virus that predominantly presents with fever,
fatigability, respiratory symptoms including nonproductive cough
and shortness of breath. Multiple organ involvement including
cardiac, gastrointestinal, reticuloendothelial system and neurolog-
ical involvement have been reported [2-4]. Neurological manifes-
tations are being reported infrequently. In a study by Mao et al.,
36.4% (n=78) of patients had evidence of neurological involve-
ment, among which 24.8% (n=53) of patients had evidence of cen-
tral nervous system (CNS) involvement. Among those who had
CNS involvement, cerebrovascular events were reported in 2.8%
(n=6) patients [5]. 
Methodology 
In this review we summarize the published literature on cere-
brovascular event in patients with COVID-19 as available on the
PubMed database. We have included original studies that have
reported adult patients with cerebrovascular events as confirmed
by neurological imaging. We have excluded studies including
children, and articles under opinion and comments category. All
the articles published before 20th April 2020 have been included in
this review. 
Clinical presentation 
Studies reporting neurological involvement have reported
clinical features of headache, dizziness, impaired vision,
decreased consciousness, agitation, presence of ataxia, and seizure
in patients with COVID-19 [5-8]. However, the symptoms
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described have not been attributed to any specific etiological factor
including encephalitis, vasculitis, and cerebrovascular event. In
most scenarios patients have been evaluated for neurological
involvement following the identification of neurological symp-
toms [5,6]. Interestingly two patients have been reported to present
with hemiplegia and later diagnosed to have COVID-19 based on
their computed tomography (CT) of lungs revealing typical find-
ings. In the same study, the median duration to the onset of a cere-
brovascular event following hospital admission was reported to be
nine days. While details of CNS examination are mostly limited,
confusion as assessed by confusion assessment method, exaggerat-
ed tendon reflects, clonus and extensor plantar reflex have been
reported frequently [5,9]. However, most reported examination
findings have been bilateral suggesting a diffuse CNS process.
Clinical findings specific to patients with imaging evidence of
cerebrovascular event have not been reported in studies so far.
Unlike other infections no specific pattern of neurovascular
involvement has been reported [10-12]. 
Imaging 
Computed tomography (CT) brain and magnetic resonance
imaging (MRI) of the brain has been performed in COVID-19
patients with CNS involvement. CT brain (non-contrast) has been
done and reported more frequently, owing to the ease of availabil-
ity. MRI brain has been reported in a lesser number of patients
[5,9,12-14]. In one study reporting MRI brain findings showed
perfusion abnormalities in all 11 (100%) patients and revealed evi-
dence of ischemic stroke in 3 (23%) patients [5,9,13]. These stud-
ies did not report the site, laterality, number and pattern of
ischemic events. 
Mechanism 
While the exact mechanism by which COVID-19 leads to
multi-organ dysfunction and mortality is still being studied, several
key factors contributing to the same have been identified. 
i) It has been shown that COVID-19 similar to other coronavirus-
es use angiotensin-converting enzyme 2 (ACE-2) receptor for
entering into the cells. ACE -2 receptor is noted to be
expressed in the lungs, heart, kidneys, and endothelium.
Recent literature has shown evidence of endothelial inflamma-
tion in multiple vascular beds. Autopsy findings have revealed
the presence of viral elements and inflammatory cells within
the endothelium. Whether ACE-2 receptor involvement is
directly related to myocardial, cerebrovascular injury is still a
matter of debate [15-17]. 
ii) The exaggerated, continuous, dysfunctional and uncontrolled
activation of the immune system causing excessive cytokine
release has been consistently reported in patients with severe
pulmonary disease and cardiac involvement. Cytokine storm is
diagnosed with the presence of elevated plasma markers of
inflammation like C-reactive protein (CRP), erythrocyte sedi-
mentation rate (ESR), procalcitonin, ferritin, interleukins (IL-
2, IL-7), granulocyte - colony- stimulating factor and tumor
necrosis alpha. In the studies reporting CNS involvement and
cerebrovascular events, a significant difference in the levels of
these inflammatory markers has not been proven to predict
clinical presentation or outcome [1,2,15]. 
iii) Embolic events as noted by elevated d-dimer, serum cardiac
markers including high-sensitivity troponin and proBNP have
been consistently reported. Patients are also reported to be at a
higher risk of arrhythmia secondary to myocarditis possibly
precipitating embolism [5,15,16,18]. 
iv) Other postulated mechanisms have been a) A prothrombotic
state as noted by elevated d-dimer, fibrinogen, lactate dehydro-
genase and other markers of coagulation, b) hypoxia induced
ischemia and apoptosis, c) secondary to hemophagocytic lym-
phohistiocytosis, d) possible disruption of plaque secondary to
the presence of risk factor and inflammation, e) coagulopathy
and thrombocytopenia [6,9,19,20]. 
While multiple mechanisms have been postulated cytokine
storm has been shown to correlate with the severity of illness,
acute respiratory distress syndrome (ARDS), acute cardiac injury,
acute renal failure, the requirement of invasive and noninvasive
mechanical ventilation, morbidity (hospital and ICU length of
stay) and mortality [2,15,18,21]. 
COVID-19 in patients with prior cerebrovascular
disease 
Most studies have reported a history of cardiovascular and
cerebrovascular disease (CVD) together in comorbidities. Most of
the available literature also supports the presence of cardio-cere-
brovascular comorbidities as a predictor for severe illness [8,15].
Guan et al. reported the presence of cerebrovascular disease to be
an independent factor linked with poor outcome. They included
1099 patients among which 1.4% (n=15) had a history of cere-
brovascular disease. In this study, they also showed that the pres-
ence of cerebrovascular disease was higher among patients with
severe illness (2.3%) as compared to patients with mild illness
(1.1%) [22]. However, this was not statistically significant. Risk
factors of cerebrovascular disease including older age, hyperten-
sion, diabetes, hyperlipidemia, smoking is also significantly higher
among patients with severe infection [15,18,23]. Aggarwal et al.
did a pooled analysis of the published literature on severity of
COVID-19 among patients with past history of CVD. They identi-
fied 6 studies of COVID-19 which included patients with prior
CVD. They independently analyzed four studies comparing pres-
ence of cerebrovascular disease in severe vs non-severe COVID-
19 cases. Interestingly they reported that patients with history of
CVD had a 2.5-fold increase in odds of severe COVID-19 illness
[24]. All these studies have not been able to show an association of
increased mortality with prior CVD [25].
Outcome
Mortality in patients with COVID-19 is 2-4% in general pop-
ulation, which is higher as compared to seasonal flu. Mortality in
critically ill patients is as high as 49% [2]. Advanced age, ARDS,
acute cardiac injury, prior vascular comorbidities, elevated inflam-
matory markers are linked with mortality [2,5]. Diffuse CNS
involvement has been reported to be higher among patients with
severe illness. Only three studies have specifically reported
patients with newly diagnosed cerebrovascular disease as shown in
Table 1. The study by Mao et al. reported that the presence of cere-
brovascular disease as identified by the CT brain (non-contrast)
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was higher among patients with severe infection and it was statis-
tically significant. The other two studies were conducted in
patients that were directly admitted to ICU due to higher severity
of illness at onset [5,9,16]. However, these two studies did not
compare morbidity or mortality in the subset of patients develop-
ing new onset cerebrovascular disease (with rest of the patients)
owing to low event rates. 
Future direction
Most studies have failed to report the role of medications
including agents affecting renin –angiotensin– aldosterone,
statins, antiplatelet agents, and anticoagulants uniformly
[18,21,26]. The roles of CNS depressants including opioids, ben-
zodiazepines, neuromuscular blocking agents on case identifica-
tion and screening for neurological deficits among critically ill
patients still needs consideration [12,13,19]. Multiple medications
that are used for treatment, their role in cerebrovascular events
and long term outcome still require clarification [12,14,27]. The
exact mechanisms with which patients suffer cerebrovascular
events and how these events attribute to poor outcome require fur-
ther understanding [28]. 
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